Tag: VaxNewMo

VaxNewMo is developing next generation conjugate vaccines against bacterial diseases using its patented conjugating enzyme technology. Our conjugating enzyme technology is faster, more natural, and more reliable than methods used by pharmaceutical companies.

Learn more about VaxNewMo at www.linkedin.com/company/vaxnewmo.

VaxNewMo’s Vaccine Breakthrough Published in Nature

St. Louis bioscience startup VaxNewMo is developing broader and more affordable vaccines faster with its patented technology. The company’s breakthrough research is currently featured in Nature Magazine's Communications section.Publication in this...

A “No” from Arch Grants Isn’t a “No” to Your Business

August saw the finalist pitch day of the Arch Grants Global Startup Competition, which constitutes the final round of selection where an external panel of judges will decide who will receive...

Bioscience Startup Founders: Expect Bumps in the Road From Academic to Entrepreneur

After receiving his Ph.D. in biomedical sciences, Christian Harding embarked on a post-doc fellowship that soon evolved into VaxNewMo, a biotech company developing antibacterial vaccines. Although his new company was built...

Meet the Next Generation of Job Creators Winning in St. Louis

St. Louis’ Innovation Community gave the region's top startups the chance to present their companies to a packed house of entrepreneurs, investors, and other members of the innovation community at the...

18 Startups Win $50,000 Each To Locate Their Business In St Louis

Arch Grants has awarded $900,000 in grant funds to 18 new startups and early-stage businesses. The winners were announced at the 5th annual Arch Grants Gala on Friday night.Each of...

Latest Stories

Popular Stories